Investors and mediaWe provide treatments and support services within oncology, neurology, metabolics, and immunology. Latest reports Cycle Pharma 2025 Accounts20th May 2026Read More Cycle Pharma 2024 Accounts9th July 2025Read More Cycle Pharma 2023 Accounts14th October 2024Read More Latest news New telehealth service to help people diagnosed with Alkaptonuria2nd September 2026Read More Cycle Pharmaceuticals launches CAVHANZA™ (nilotinib) Orally Disintegrating Tablets (ODT), designed for use with PPIs and H2RAs without food restrictions124th August 2026Read More CAVHANZA™ (nilotinib) Orally Disintegrating Tablets: a new, FDA-approved treatment2nd June 2026Read More
